Matthew Royle

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice.

Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly.

A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors. He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.

Afficher le CV complet Masquer le CV complet

Carrière

Since 2015	Partner, Taylor Wessing
2011 - 2015	Senior Associate, Taylor Wessing
2006 - 2011	Associate, Taylor Wessing

2004 - 2006

Trainee solicitor, Taylor Wessing

Voir plus Moins

Formation

2007	Diploma in Intellectual Property Law, Bristol University, UK
2006	Admitted to the Bar, England and Wales
2002	PhD, Molecular Immunology, University of Cambridge, UK

1998

Degree, Medical Microbiology, University of Edinburgh, UK

Voir plus Moins

Publications

EU Guidance on biosimilar MAbs - what took so long?, Scrip Regulatory Affairs, pp 10-12, 17, July 2012
Neurim - EU Advocate General argues that supplementary protection certificates should be allowed for usage patents, Scrip Regulatory Affairs, p 5, 22, May 2012

Groupes & Associations

Associate member of CIPA

Langues étrangères

English

Expertise

Services et Groupes Brevets et innovation Résolution des litiges Réglementation des soins de santé Litiges en matière de PI Contentieux en nouvelles technologies Règlementation des sciences de la vie Résolution des litiges brevets et savoir-faire

Secteurs Sciences de la vie et Santé Biotech Dispositifs médicaux Produits pharmaceutiques

Experience

A life sciences company	A life sciences company on market formation dates in relation to orphan medicinal products.
A life sciences company	A life sciences company on the validity of and expiry of supplementary protection certificates for a product launch.
A life sciences company	A life sciences company on an EPO opposition in relation to a pharmaceutical.

A company dealing with commercialisation arrangements for university discoveries	A company dealing with commercialisation arrangements for university discoveries on a dispute between co-inventors in relation to a patent.
A life sciences company	A life sciences company on data exclusivity in relation to a combination product in the context of a sale of that product.

Voir plus Moins

Prix et distinctions

Chambers and Partners UK 2023	Life Sciences (IP/patent litigation) - Band 2: Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. Prior to his legal career he undertook a doctorate in medical microbiology. "A well-respected litigator." "Matthew Royle is clearly very clever and good at managing challenging situations."
Chambers and Partners UK 2023	Intellectual Property (patent litigation) - Band 3: Matthew Royle acts for pharmaceutical companies in patent litigation and also advises them on SPCs and regulation. He has taken a number of cases to the UK Supreme Court.
Chambers UK 2022	Life Sciences - IP/Patent Litigation: "A good litigator, with a good knowledge of the life sciences sector. He has a particular focus on the generics side."
Chambers UK 2022	Intellectual Property - Patent Litigation
Managing IP EMEA Awards 2020	"The Impact Case of the Year" for Actavis v ICOS case, where we acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).
Chambers UK 2019	Leading individual - Life Sciences: IP/Patent (band 3) and IP: patent litigation (band 4).
Chambers UK 2020	Leading individual - Life Sciences: IP/Patent litigation (Band 3): Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. A source says: "He is a very good patent litigator – sensible, pragmatic and a pleasure to work with."
Chambers UK 2020	Leading individual - Intellectual Property: Patent litigation (Band 4): Matthew Royle acts for pharmaceuticals companies in patent litigation and also advises them on SPCs and regulation. A source says: "He is a very good patent litigator - sensible, pragmatic and a pleasure to work with."
Legal 500 UK 2020	Leading individual - TMT: Pharmaceuticals and Biotech
IAM Patent 1000 United Kingdom: England 2019	Leading individual: litigation (Bronze): Matthew Royle is a canny and highly trained harvester of SPC extensions – a “well-known, longstanding presence in intellectual property”.
Who's Who Legal 2019	Leading individual: Patents
Managing Intellectual Property - IP Stars 2019	Patent star
Times Lawyer of the Week 2018	For Pregabalin Supreme Court case
Chambers UK 2019	Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a patent litigator and pharmaceuticals regulation expert with an academic background in medical microbiology. A source says: "He is a real hands-on partner in a lot of major cases."
Chambers UK 2019	Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is known for representing generic pharmaceutical manufacturers in high-stakes patent litigation such as patent revocation actions and disputes concerning contested SPCs. A source says: "He is a real hands-on partner in a lot of major cases."
Chambers UK 2018	Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a rising life sciences patent litigator whose recent work has involved questions of secondary medical uses, dosage regimes and SPCs. A market commentator says he is "very strong on the science."
Chambers UK 2018	Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is distinguished for his representation of generic pharmaceutical manufacturers in high-value patent revocation actions and cases concerning SPCs. Sources note that he is "very strong on the science."
Legal Week Rising Stars	‘Rising star’ in litigation